A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The “Border-Time” Bias
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14215265
Abstract: Simple Summary Target-oriented drugs are profoundly changing the anti-cancer treatments. Progression-free survival is a primary or co-primary endpoint in the large part of comparative and translational clinical trials about target-oriented anti-cancer agents. In this context,… read more here.
Keywords: time; time bias; clinical trials; anti cancer ... See more keywords